This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Loyd, R. G. Articles by Mertz, G. H. Search for Related Content PubMed PubMed Citation Articles by Loyd, R. G. Articles by Mertz, G. H. Social Bookmarking                         What's this?

Failure of Pentoxifylline for End-stage Peripheral Vascular Disease

Surgical Resident, Phoenix Integrated Surgical Residency; Phoenix, Arizona

Gregory W. Prian

Clinical Assistant Professor of Surgery, University of Arizona; Phoenix, Arizona

Henry Gomez

Vascular Technician, Kidney Disease Center; Phoenix, Arizona

James Laub

Chief Clinical Section Pharmacy Service, VA Medical Center, Phoenix, Arizona

George H. Mertz

Director, Southwest Regional Medical Education Center, Long Beach, California

In this trial of pentoxifylline, 15 patients with end-stage peripheral vascular disease had symptoms severe enough to warrant operation, but surgery was contraindicated because of anatomically noncorrectable disease, serious medical problems, or refusal. Their mean age was sixty-six years. Each patient received oral pentoxifylline, 400 mg tid, for twelve weeks. Pentoxifylline had no measurable clinical benefit in 14 of the patients. In addition, the authors noted an increased incidence of symptomatic coronary artery insufficiency during the trial period that may or may not have been drug related.

Angiology, Vol. 38, No. 4, 304-308 (1987)
DOI: 10.1177/000331978703800404


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?